See more : Athene Holding Ltd. (ATH) Income Statement Analysis – Financial Results
Complete financial analysis of Aldeyra Therapeutics, Inc. (ALDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aldeyra Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Trilogy Metals Inc. (TMQ.TO) Income Statement Analysis – Financial Results
- Mattioli Woods plc (MTW.L) Income Statement Analysis – Financial Results
- Norwegian Block Exchange AS (NBX.OL) Income Statement Analysis – Financial Results
- Petrel Resources Plc (PET.L) Income Statement Analysis – Financial Results
- AnGes, Inc. (4563.T) Income Statement Analysis – Financial Results
Aldeyra Therapeutics, Inc. (ALDX)
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -262.78K | -258.71K | -264.18K | -56.22K | -96.31K | -71.00K | -37.85K | -35.79K | -18.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.46M | 47.31M | 44.94M | 24.68M | 44.35M | 29.82M | 16.30M | 13.18M | 7.57M | 3.71M | 1.54M | 469.27K | 1.36M |
| General & Administrative | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.34M | 15.37M | 11.28M | 9.99M | 12.15M | 9.88M | 6.19M | 5.52M | 4.41M | 3.56M | 2.13M | 644.94K | 743.94K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.33M | 720.79K | -21.48M | 5.41K |
| Operating Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Cost & Expenses | 42.79M | 62.68M | 56.22M | 34.67M | 56.51M | 39.70M | 22.49M | 18.70M | 11.99M | 7.27M | 3.68M | 1.11M | 2.11M |
| Interest Income | 7.32M | 2.35M | 185.36K | 292.22K | 1.54M | 952.70K | 261.25K | 102.04K | 11.13K | 3.00 | 31.00 | 101.00 | 5.00K |
| Interest Expense | 2.07M | 1.69M | 1.74M | 1.90M | 603.85K | 146.79K | 113.45K | 105.51K | 112.31K | 244.17K | 159.32K | 342.01K | 279.93K |
| Depreciation & Amortization | 262.78K | 258.71K | 264.18K | 56.22K | 96.31K | 71.00K | 37.85K | 35.79K | 18.78K | 1.07K | 31.00 | 3.74K | 1.59K |
| EBITDA | -35.21M | -60.07M | -55.77M | -36.07M | -61.44M | -38.68M | -22.19M | -18.56M | -11.96M | -4.94M | 13.22M | -22.73M | -2.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.79M | -62.68M | -56.22M | -36.42M | -63.07M | -39.70M | -22.49M | -18.70M | -11.99M | -7.27M | -3.68M | -1.11M | -2.11M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.25M | 655.35K | -1.56M | -3.37M | -5.63M | 805.91K | 147.80K | -3.47K | -101.18K | 2.08M | 16.74M | -21.96M | -269.53K |
| Income Before Tax | -37.54M | -62.02M | -57.78M | -38.03M | -62.14M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -655.35K | 1.48M | -479.27K | -1.31M | 952.70K | 223.40K | 66.25K | -7.65K | 243.11K | 159.29K | -21.14M | 285.34K |
| Net Income | -37.54M | -61.37M | -59.25M | -37.55M | -60.83M | -38.89M | -22.34M | -18.70M | -12.09M | -5.19M | 13.06M | -23.07M | -2.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.36 | 39.90 | -5.72 | -7.26 |
| EPS Diluted | -0.64 | -1.05 | -1.10 | -1.11 | -2.24 | -1.79 | -1.40 | -1.65 | -1.40 | -1.35 | 2.72 | -5.10 | -0.50 |
| Weighted Avg Shares Out | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.82M | 327.37K | 4.04M | 327.37K |
| Weighted Avg Shares Out (Dil) | 58.94M | 58.41M | 54.04M | 33.97M | 27.11M | 21.69M | 15.92M | 11.35M | 8.63M | 3.85M | 4.80M | 4.52M | 4.80M |
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate...
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
The FDA accepts Aldeyra's resubmitted NDA for topical ocular reproxalap to treat the signs and symptoms of dry eye disease. Stock rises.
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Aldeyra conducted a Phase 3 trial, where reproxalap met its primary endpoint in...
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Tomasz Stryjewski, M.D., Chief Medical Advisor - Retina, will present at the...
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the resubmission of a New Drug Application (NDA) to the U.S. Food and...
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction...
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the completion of enrollment in a Phase 3 dry eye chamber clinical trial...
Aldeyra Therapeutics to Host Investor Roundtable Q&A
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday,...
Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission
Aldeyra Therapeutics offers a high-risk/high-reward investment opportunity with its Reproxalap program and promising pipeline beyond Reproxalap. Reproxalap has shown positive results in preclinical and clinical trials for the treatment of dry eye disease and allergic conjunctivitis. Aldeyra plans to resubmit...
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a...
Source: https://incomestatements.info
Category: Stock Reports